Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

医学 伊马替尼 中止 内科学 甲磺酸伊马替尼 中期分析 前瞻性队列研究 髓系白血病 外科 临床试验
作者
François‐Xavier Mahon,Delphine Réa,Joëlle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Étienne,Josy Reiffers,Philippe Rousselot
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:11 (11): 1029-1035 被引量:1521
标识
DOI:10.1016/s1470-2045(10)70233-3
摘要

Background Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether treatment can safely be discontinued in the long term. We aimed to assess whether imatinib can be discontinued without occurrence of molecular relapse in patients in complete molecular remission (CMR) while on imatinib. Methods In our prospective, multicentre, non-randomised Stop Imatinib (STIM) study, imatinib treatment (of >2 years duration) was discontinued in patients with CML who were aged 18 years and older and in CMR (>5-log reduction in BCR–ABL and ABL levels and undetectable transcripts on quantitative RT-PCR). Patients who had undergone immunomodulatory treatment (apart from interferon α), treatment for other malignancies, or allogeneic haemopoietic stem-cell transplantation were not included. Patients were enrolled at 19 participating institutions in France. In this interim analysis, rate of relapse was assessed by use of RT-PCR for patients with at least 12 months of follow-up. Imatinib was reintroduced in patients who had molecular relapse. This study is registered with ClinicalTrials.gov, number NCT00478985. Findings 100 patients were enrolled between July 9, 2007, and Dec 17, 2009. Median follow-up was 17 months (range 1–30), and 69 patients had at least 12 months follow-up (median 24 months, range 13–30). 42 (61%) of these 69 patients relapsed (40 before 6 months, one patient at month 7, and one at month 19). At 12 months, the probability of persistent CMR for these 69 patients was 41% (95% CI 29–52). All patients who relapsed responded to reintroduction of imatinib: 16 of the 42 patients who relapsed showed decreases in their BCR–ABL levels, and 26 achieved CMR that was sustained after imatinib rechallenge. Interpretation Imatinib can be safely discontinued in patients with a CMR of at least 2 years duration. Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors. Funding French Ministry of Health (Programme Hospitalier de Recherche 2006 grants), Institut National du Cancer (INCA).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
匆匆发布了新的文献求助10
刚刚
刚刚
刚刚
plddd完成签到,获得积分10
刚刚
小宋完成签到,获得积分0
1秒前
1秒前
itsdeva发布了新的文献求助10
2秒前
gg发布了新的文献求助10
2秒前
2秒前
2秒前
三哥秦发布了新的文献求助10
3秒前
3秒前
4秒前
4秒前
ou发布了新的文献求助10
4秒前
zjy发布了新的文献求助10
4秒前
5秒前
5秒前
plddd发布了新的文献求助30
5秒前
森海完成签到,获得积分10
5秒前
6秒前
匆匆发布了新的文献求助10
6秒前
6秒前
7秒前
跳越光子发布了新的文献求助10
7秒前
张贵川完成签到 ,获得积分10
7秒前
霸气的小熊猫完成签到,获得积分20
7秒前
一品真意完成签到,获得积分10
8秒前
小蘑菇的应助被Derek采纳,获得10
8秒前
Lee发布了新的文献求助10
8秒前
April发布了新的文献求助10
9秒前
乐观碧彤发布了新的文献求助10
9秒前
开朗啤酒发布了新的文献求助10
9秒前
冰夜雨发布了新的文献求助10
10秒前
诸沧海发布了新的文献求助10
10秒前
11秒前
酸甜完成签到,获得积分10
11秒前
11秒前
11秒前
高挑的豪完成签到 ,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193729
求助须知:如何正确求助?哪些是违规求助? 9579876
关于积分的说明 21868333
捐赠科研通 7793519
什么是DOI,文献DOI怎么找? 3437414
关于科研通互助平台的介绍 2560856
邀请新用户注册赠送积分活动 2484216